MCID: AGR002
MIFTS: 44

Agoraphobia

Categories: Mental diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Agoraphobia

MalaCards integrated aliases for Agoraphobia:

Name: Agoraphobia 11 75 53 43 14 16 71 31 33
Fear of Open Spaces 11
Phobia of Going out 33

Classifications:



External Ids:

Disease Ontology 11 DOID:593
MeSH 43 D000379
NCIt 49 C34362
SNOMED-CT 68 154885006
ICD10 31 F40.0
ICD11 33 530592394
UMLS 71 C0001818

Summaries for Agoraphobia

Disease Ontology: 11 A phobic disorder involving the specific anxiety about being in a place or situation where escape is difficult or embarrassing or where help may be unavailable.

MalaCards based summary: Agoraphobia, also known as fear of open spaces, is related to personality disorder and obsessive-compulsive disorder. An important gene associated with Agoraphobia is HTR1A (5-Hydroxytryptamine Receptor 1A), and among its related pathways/superpathways are Monoamine transport and Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics. The drugs Dopamine and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include brain, amygdala and temporal lobe, and related phenotypes are Decreased viability and nervous system

Wikipedia: 75 Agoraphobia is a mental and behavioral disorder, specifically an anxiety disorder characterized by... more...

Related Diseases for Agoraphobia

Diseases related to Agoraphobia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 165)
# Related Disease Score Top Affiliating Genes
1 personality disorder 31.0 SLC6A4 MAOA HTR1A COMT
2 obsessive-compulsive disorder 30.7 SLC6A4 MAOA HTR1A COMT
3 hypochondriasis 30.6 SLC6A4 PIR MAOA HTR1A
4 avoidant personality disorder 30.4 SLC6A4 PIR MAOA
5 panic disorder 30.4 TMEM132D SLC6A4 SLC6A2 PTK7 NPSR1 MIR22
6 alcohol use disorder 30.4 SLC6A4 PRODH MAOA COMT
7 dependent personality disorder 30.4 PIR MAOA
8 endogenous depression 30.4 SLC6A4 MAOA HTR1A COMT
9 post-traumatic stress disorder 30.3 SLC6A4 MAOA HTR1A COMT
10 acute stress disorder 30.3 SLC6A4 PIR
11 neurotic disorder 30.3 SLC6A4 MAOA HTR1A COMT
12 eating disorder 30.3 SLC6A4 LOC110806262 HTR1A HCRTR1 COMT
13 separation anxiety disorder 30.3 SLC6A4 MAOA HTR1A CTU2 COMT
14 obsessive-compulsive personality disorder 30.2 SLC6A4 PIR COMT
15 irritable bowel syndrome 30.1 SLC6A4 HTR1A COMT
16 atypical depressive disorder 30.1 SLC6A4 MAOA HTR1A
17 bulimia nervosa 30.0 SLC6A4 MAOA COMT
18 melancholia 30.0 SLC6A4 MAOA HTR1A COMT
19 social phobia 30.0 SLC6A4 PRODH PIR MAOA LOC110806262 HTR1A
20 alcohol dependence 29.9 SLC6A4 NOS1 MAOA LOC110806262 HTR1A COMT
21 major depressive disorder 29.9 SLC6A4 SLC6A2 PIR NOS1 MAOA HTR1A
22 anxiety 29.9 TMEM132D SLC6A4 SLC6A2 PTK7 PRODH NPSR1
23 anterograde amnesia 29.8 PRODH HTR1A
24 drug dependence 29.8 SLC6A4 MAOA COMT
25 sleep disorder 29.8 SLC6A4 HTR1A HCRTR1 COMT
26 borderline personality disorder 29.8 SLC6A4 MAOA HTR1A COMT
27 cyclothymic disorder 29.7 SLC6A4 PIR HTR1A COMT
28 tobacco addiction 29.7 SLC6A4 MAOA HTR1A COMT
29 disease of mental health 29.6 SLC6A4 PRODH MIR22 MAOA HTR1A COMT
30 mood disorder 29.6 SLC6A4 SLC6A2 PRODH NOS1 MAOA HTR1A
31 phobia, specific 29.6 TMEM132D SLC6A4 PRODH PIR MAOA HTR1A
32 gilles de la tourette syndrome 29.6 SLC6A4 SLC6A2 MAOA HTR1A COMT
33 bipolar disorder 29.5 SLC6A4 SLC6A2 PRODH NOS1 MAOA HTR1A
34 generalized anxiety disorder 29.4 SLC6A4 SLC6A2 PRODH PIR MAOA LOC110806262
35 psychotic disorder 29.3 SLC6A4 PRODH NOS1 MIR22 MAOA HTR1A
36 dysthymic disorder 29.3 SLC6A4 SLC6A2 PRODH PIR MAOA HTR1A
37 tic disorder 29.2 SLC6A4 SLC6A2 PRODH MAOA HTR1A COMT
38 attention deficit-hyperactivity disorder 28.8 SLC6A4 SLC6A2 PRODH PIR MAOA LOC110806262
39 schizophrenia 28.8 SLC6A4 SLC6A2 PRODH NOS1 MAOA HTR1A
40 phobic disorder 28.6 TMEM132D SLC6A4 PTK7 PRODH PIR MAOA
41 panic disorder 1 11.2
42 cascade stomach 10.3 SLC6A4 HTR1A
43 psychosexual disorder 10.3 SLC6A4 HTR1A
44 severe combined immunodeficiency 10.3
45 pedophilia 10.3 SLC6A4 MAOA
46 inhibited male orgasm 10.3 SLC6A4 MAOA HTR1A
47 serotonin syndrome 10.2 SLC6A4 MAOA HTR1A
48 retrograde amnesia 10.2 SLC6A4 HTR1A
49 amphetamine abuse 10.2 SLC6A4 SLC6A2
50 adjustment disorder 10.2 SLC6A4 PIR HTR1A

Graphical network of the top 20 diseases related to Agoraphobia:



Diseases related to Agoraphobia

Symptoms & Phenotypes for Agoraphobia

GenomeRNAi Phenotypes related to Agoraphobia according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00249-S 9.32 SLC6A4
2 Decreased viability GR00381-A-1 9.32 GRP HTR1A SLC6A4
3 Decreased viability GR00381-A-3 9.32 GRP HTR1A SLC6A4
4 Decreased viability GR00386-A-1 9.32 GRP
5 Decreased viability GR00402-S-2 9.32 GRP HTR1A

MGI Mouse Phenotypes related to Agoraphobia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.97 CCKBR COMT GLRB GRP HCRTR1 HTR1A
2 cardiovascular system MP:0005385 9.73 CCKBR COMT GLRB GRP HTR1A MAOA
3 behavior/neurological MP:0005386 9.5 CCKBR COMT GLRB GRP GRPR HCRTR1

Drugs & Therapeutics for Agoraphobia

Drugs for Agoraphobia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 31)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
2
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
3
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
4
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
5
Citalopram Approved Phase 4 59729-32-7, 59729-33-8 2771
6
Sertraline Approved Phase 4 79617-96-2 68617
7
Dexetimide Withdrawn Phase 4 21888-98-2 30843
8 Central Nervous System Stimulants Phase 4
9 Dopamine Uptake Inhibitors Phase 4
10 Dopamine Agents Phase 4
11 GABA Modulators Phase 4
12 Cytochrome P-450 Enzyme Inhibitors Phase 4
13 Neurotransmitter Agents Phase 4
14 Psychotropic Drugs Phase 4
15 Antidepressive Agents Phase 4
16 Serotonin Uptake Inhibitors Phase 4
17
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
18
Lecithin Approved, Experimental, Investigational, Nutraceutical Phase 3 8002-43-5, 1446756-47-3, 18656-38-7 26197 9547096 6323481
19 Anticonvulsants Phase 3
20 Sunflower Phase 3
21
Cycloserine Approved Phase 2 68-41-7 6234
22 Anti-Bacterial Agents Phase 2
23 Anti-Infective Agents Phase 2
24 Antimetabolites Phase 2
25 Antitubercular Agents Phase 2
26 Antibiotics, Antitubercular Phase 2
27
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
28
Tannic acid Approved 1401-55-4 16129878 16129778
29
Magnesium sulfate Approved, Investigational, Vet_approved 7487-88-9
30
Nicotine Approved 54-11-5 942 89594
31 Pharmaceutical Solutions

Interventional clinical trials:

(show top 50) (show all 55)
# Name Status NCT ID Phase Drugs
1 A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity Unknown status NCT03785223 Phase 4 Methylphenidate Hydrochloride Controlled-Release Capsules;Placebo Capsule
2 Long-term, Open, Naturalistic, Randomized Clinical Trial With Clonazepam and Paroxetine in Panic Disorder With or Without Agoraphobia Completed NCT02852577 Phase 4 Clonazepam;Paroxetine
3 Comparative Effectiveness of Mindfulness-Based Stress Reduction and Pharmacotherapy for Anxiety Completed NCT03522844 Phase 4 Escitalopram
4 Sertraline in the Treatment of Generalized Social Phobia With Comorbidity Terminated NCT00182533 Phase 4 Sertraline;Placebo
5 Mechanisms of CBT-Treatment Effects in Patients With Panic Disorder and Panic Disorder With Agoraphobia: The Role of Interoceptive Exposure Unknown status NCT01323556 Phase 2, Phase 3
6 Dynamic Treatment vs. CBT for Panic Disorder Completed NCT00353470 Phase 3
7 Treatment of Panic Disorder: Long Term Strategies Completed NCT00000368 Phase 3 Paroxetine or other medication - algorithm used
8 Parent-based Treatment for Youth With Anxiety and Obsessive-compulsive Disorder: Comparison of Therapist-Led and Therapist Assisted Approaches Recruiting NCT04922502 Phase 2, Phase 3
9 Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study Not yet recruiting NCT03549819 Phase 3 Cannabidiol (CBD) Oil Capsules;Sunflower Lecithin Oil in Capsule
10 Cannabinoids for the Treatment of Anxiety Disorders: An 8-Week Pilot Study Withdrawn NCT04569760 Phase 3 50:2 mg(CBD:THC)/ml - Cannabinoid Oil Oral Preparation- titrated as tolerated up to a maximum 8mls twice daily (200 mg- 800 mg total dose);Placebo Oil
11 Augmentation of Exposure Therapy With D-Cycloserine in Patients With Agoraphobia With or Without Panic Disorder Completed NCT01928823 Phase 2 D-Cycloserine
12 Intensive Treatment of Adolescent Panic and Agoraphobia Completed NCT00576719 Phase 2
13 The Modular Protocol for Mental Health (MPMH): A Pilot Randomised Clinical Trial of a Transdiagnostic Psychological Treatment for Mood and Anxiety Disorders in Adults Completed NCT03143634 Phase 1, Phase 2
14 Construction of a Questionnaire on Panic Disorder and Agoraphobia Unknown status NCT03885453
15 A Comparative Controlled Study of Virtual Reality Therapy and Cognitive Behavior Therapy in Panic Disorder With Agoraphobia Unknown status NCT00129610
16 Effect of Mindfulness Meditation on Physiological Response to Unpredictable Stimuli Unknown status NCT03206437
17 Exposure Initializes Therapy - Treatment Of Homebound Patients Extended Unknown status NCT04460378
18 Effect of Cognitive-behavior Therapy on Panic Symptomatology and the Activation of the Brain's Fear Network to Panic-related Body Symptoms in Patients With Panic Disorder Completed NCT04568109
19 Trans-diagnostic Group CBT vs. Standard Group CBT for Depression, Social Anxiety and Agoraphobia/Panic Disorder: A Pragmatic, Multicenter Non-inferiority Randomized Controlled Trial Completed NCT02954731
20 Efficacy of Hypnotherapy Compared to a Wait-list Control Group in the Treatment of Agoraphobia Completed NCT03684577
21 Evaluation of Occupational Balance, Fear and Agoraphobia in Adults Completed NCT04681261
22 Effectiveness of Specific Model of Cognitive-Behavioral Therapy in Panic Disorder Patients With Agoraphobia Completed NCT00772746
23 The Influence of Physical Activity (Prior to In-vivo Exposure) on the Effect of Cognitive Behavioural Therapy in Patients With Panic Disorder and Agoraphobia Completed NCT01928810
24 Virtual Reality for Panic Disorder With Agoraphobia: a Clinical Trial Completed NCT03101332
25 Moderators and Mediators of Treatment Change in Panic Disorder and Agoraphobia Completed NCT03547180
26 Vestibular Dysfunction In Adult Patients With Panic Disorder With or Without Agoraphobia Completed NCT00004367
27 Thought Field Therapy and Cognitive Therapy for Agoraphobia - a Randomized Controlled Intervention Study Where the Efficacy of Thought Field Therapy is to be Compared to Cognitive Therapy Completed NCT00932919
28 The Influence of Physical Activity on the Effect of Cognitive Behavioural Therapy, Neurobiological Parameters and Information Processing in Patients With Panic Disorder With/Without Agoraphobia Completed NCT01788800
29 Longterm Outcome of Inpatient Cognitive and Behavioral Therapies for Panic Disroder and Agoraphobia Completed NCT01446172
30 Internet-based Exposure Therapy for Panic Disorder: A Randomized Controlled Pilot Study Completed NCT03061448
31 Examining the Effects of Reduced Environmental Stimulation on Anxiety Completed NCT03051074
32 Predicting Treatment Response to Exposure Therapy Using a CO2 Habituation Paradigm in Patients With High Levels of Anxiety Sensitivity Completed NCT03925987
33 Providing Tools for Effective Care and Treatment of Anxiety Disorders (AD): Outcomes, Mediators and Moderators of Enhanced Extinction Completed NCT02605668
34 Virtual Reality Exposure Therapy in Agoraphobic Participants Completed NCT00734370
35 Phase 2/3 Study of Panic Control Treatment vs Panic-Focussed Psychodynamic Psychotherapy Under Randomized and Self-Selection Conditions Completed NCT01606592
36 Dimensional Brain Behavior Predictors of CBT Outcomes in Pediatric Anxiety Completed NCT02810171
37 Cognitive-behavioural Therapyin Panic Disorder: the Preparation of Patients With Panic Disorder for Interoceptive and in Vivo Agoraphobic Exposure Completed NCT01025908
38 Improving Access to Treatment of Anxiety and Depression in Young Adults Using Transdignostic iCBT: Feasibility of a Translated Version of an Empirically Supported Program Completed NCT03156556
39 Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder, a Prospective, Randomized Pilot Study With Wait List as Control Group. Completed NCT00202709
40 Pilot Study of Vestibular Rehabilitation Training for Panic Disorder With Vestibular Dysfunction Completed NCT00004366
41 A Pragmatic Randomized Controlled Trial of Group Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders in Primary Care Completed NCT02811458
42 Effectiveness of Cognitive Behavioral Short-term Treatment for Adolescents With Emotional Symptom Problems in Community Clinics in Norway. A Randomized Controlled Study Completed NCT02150265
43 The Effect of a Transdiagnostic, Self-guided Internet Intervention ("Velibra") for Waitlist Patients With Anxiety Disorders Recruiting NCT04793828
44 Cognitive Behavior Therapy vs Exposure in Vivo in the Treatment of Panic Disorder With Agoraphobia Recruiting NCT01680237
45 Ambulante Leitlinienkonforme Intervention im Selbstmanagement für Angststörungen (ALISA) Recruiting NCT05510804
46 Building an Outcomes Assessment Infrastructure to Assess Youth in the McLean Anxiety Mastery Program at McLean Hospital Recruiting NCT02305537
47 SoREAL- a Randomized Clinical Trial Recruiting NCT03845101
48 A Comparison of the Efficacy of Transdiagnostic Behavior Therapy and Disorder-specific Therapy in Veterans With PTSD, Anxiety, and Depression Recruiting NCT04293341
49 Comparison of Patient-Centered Versus Provider-Centered Delivery of Cognitive Behavioral Treatment (CBT) for Pediatric Anxiety and Obsessive Compulsive Disorder (OCD) Recruiting NCT03528109
50 Respiratory Training vs Interoceptive Exposure in the Treatment of Transdiagnostic Pathological Anxiety: A Randomized Clinical Trial Recruiting NCT05427708

Search NIH Clinical Center for Agoraphobia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Alprazolam

Cochrane evidence based reviews: agoraphobia

Genetic Tests for Agoraphobia

Anatomical Context for Agoraphobia

Organs/tissues related to Agoraphobia:

MalaCards : Brain, Amygdala, Temporal Lobe, Cingulate Cortex, Heart, Cortex, Pituitary

Publications for Agoraphobia

Articles related to Agoraphobia:

(show top 50) (show all 3228)
# Title Authors PMID Year
1
Associations between serotonin-related gene polymorphisms and panic disorder. 53 62
15670397 2005
2
Norepinephrine transporter (NET) promoter and 5'-UTR polymorphisms: association analysis in panic disorder. 53 62
15722184 2005
3
Association of a functional 1019C>G 5-HT1A receptor gene polymorphism with panic disorder with agoraphobia. 53 62
14984628 2004
4
Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder. 53 62
10870873 2000
5
Influence of personality on behavioral response to cholecystokinin-tetrapeptide in patients with panic disorder. 53 62
8771610 1996
6
A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. 53 62
7786960 1995
7
Experiences of Patients and Therapists Testing a Virtual Reality Exposure App for Symptoms of Claustrophobia: Mixed Methods Study. 62
36469413 2022
8
Anxiety and cognitive functioning in the Maastricht study: A cross-sectional population study. 62
36162695 2022
9
Virtual reality in the diagnostic and therapy for mental disorders: A systematic review. 62
36356351 2022
10
COVID-19 vaccine hesitancy in patients with mental illness: strategies to overcome barriers-a review. 62
35079435 2022
11
The Bergen 4-day treatment for panic disorder: replication and implementation in a new clinic. 62
36418989 2022
12
Estimating the Economic Value of Automated Virtual Reality Cognitive Therapy for Treating Agoraphobic Avoidance in Patients With Psychosis: Findings From the gameChange Randomized Controlled Clinical Trial. 62
36399379 2022
13
The longitudinal course of anxiety, depression and apathy through two years after stroke. 62
36063628 2022
14
Agoraphobic avoidance in patients with psychosis: Severity and response to automated VR therapy in a secondary analysis of a randomised controlled clinical trial. 62
36343472 2022
15
Incidence and risk factors for anxiety disorders in young adults: A population-based prospective cohort study. 62
36253174 2022
16
Incidences of anxiety disorders among active duty service members between 1999 and 2018. 62
36029531 2022
17
Religious Involvement and DSM-IV Anxiety Disorders Among African-Americans. 62
35605210 2022
18
Cognitive-Attentional Syndrome Moderates the Relationship Between Fear of Coronavirus and Symptoms of Coronavirus-Specific Health Anxiety. 62
36313604 2022
19
The effects of weather on depressive symptoms in patients after cardiac surgery. 62
36203385 2022
20
German translation and validation of the brief Epilepsy Anxiety Survey Instrument (brEASI). 62
35907288 2022
21
[The application of virtual reality in the treatment of mental disorders]. 62
36053303 2022
22
The effectiveness of schema therapy for patients with anxiety disorders, OCD, or PTSD: A systematic review and research agenda. 62
34296767 2022
23
Cognitive changes in health locus of control attributions after behavioral analysis in patients with panic disorder and/or agoraphobia. 62
35477084 2022
24
Comparative efficacy and acceptability of psychotherapies for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials. 62
35049483 2022
25
Fear of COVID-19 and emotional dysfunction problems: Intrusive, avoidance and hyperarousal stress as key mediators. 62
36158304 2022
26
Valproate Adjuvant Cognitive Behavioral Therapy in Panic Disorder Patients With Comorbid Bipolar Disorder: Case Series and Review of the Literature. 62
36059050 2022
27
Body Mass Index and risk for onset of mood and anxiety disorders in the general population: Results from the Netherlands Mental Health Survey and Incidence Study-2 (NEMESIS-2). 62
35918662 2022
28
Relation between anxiety disorders in adolescent mothers and dental fear in children. 62
35962616 2022
29
Not always that EASI: Validating the Russian version of the epilepsy anxiety survey instrument and its brief counterpart. 62
35753109 2022
30
Functional and structural social support in DSM-5 mood and anxiety disorders: A population-based study. 62
35421420 2022
31
A network analysis of panic symptoms in relation to depression and anxiety sensitivity in patients with panic disorder. 62
35429524 2022
32
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part I: Anxiety disorders. 62
35900161 2022
33
Relationship of behavioral inhibition to separation anxiety in a sample (N = 377) of adult individuals with mood and anxiety disorders. 62
35569286 2022
34
Age of onset of social anxiety disorder and psychiatric and mental health outcomes: Results from a nationally representative study. 62
35489557 2022
35
Effects of anxiety on sedation among pediatric patients undergoing esophagogastroduodenoscopy. 62
35452583 2022
36
Is there an elephant in the room? A study of convergences and divergences of adult attachment measures commonly used in clinical studies. 62
34983333 2022
37
Correlations of plasma oxytocin with clinical and hormonal parameters in panic disorder. 62
35714973 2022
38
French adaptation and validation of the Panic Disorder Severity Scale-self-report. 62
35761266 2022
39
Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: A randomised controlled trial. 62
35561538 2022
40
Adolescent circadian patterns link with psychiatric problems: A multimodal approach. 62
35397335 2022
41
'Thinking about Them is only making me feel worse'. The mediating role of metacognitive factors in the relationship between paranoia-like beliefs and psychopathology symptoms in a community sample. 62
35640356 2022
42
Maximizing the non-specific factors in brief cognitive behavioral therapy for panic disorder and agoraphobia: A multiple baseline case series documenting feasibility and initial efficacy. 62
35339872 2022
43
Global prevalence of anxiety and PTSD in immigrants: a systematic review and meta-analysis. 62
35147917 2022
44
Internet psychotherapeutic interventions for anxiety disorders - a critical evaluation. 62
35768807 2022
45
Elevated social anxiety symptoms across childhood and adolescence predict adult mental disorders and cannabis use. 62
35245889 2022
46
Face-to-face versus Video Teleconference Group Cognitive Behavioural Therapy for Anxiety and Related Disorders: A Preliminary Comparison. 62
34159838 2022
47
Self-guided digital treatment with virtual reality for panic disorder and agoraphobia: a study protocol for a randomized controlled trial. 62
35597959 2022
48
An interpretable radiomics model for the diagnosis of panic disorder with or without agoraphobia using magnetic resonance imaging. 62
35248666 2022
49
Inpatient psychotherapy for depression in a large routine clinical care sample: A Bayesian approach to examining clinical outcomes and predictors of change. 62
35219740 2022
50
Epilepsy and Associated Factors Among Adults Hospitalized for Attempted Suicide. 62
35510836 2022

Variations for Agoraphobia

Expression for Agoraphobia

Search GEO for disease gene expression data for Agoraphobia.

Pathways for Agoraphobia

GO Terms for Agoraphobia

Cellular components related to Agoraphobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016021 10.09 CCKBR COMT GLRB GRPR HCRTR1 HTR1A
2 membrane GO:0016020 10.09 CCKBR COMT GLRB GRPR HCRTR1 HTR1A
3 plasma membrane GO:0005886 9.7 SLC6A4 SLC6A2 PTK7 NPSR1 HTR1A HCRTR1
4 plasma membrane GO:0005887 9.7 SLC6A4 SLC6A2 PTK7 NPSR1 HTR1A HCRTR1

Biological processes related to Agoraphobia according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 social behavior GO:0035176 9.88 SLC6A4 GRPR GRP
2 righting reflex GO:0060013 9.8 NPSR1 GLRB
3 dopamine catabolic process GO:0042420 9.78 MAOA COMT
4 monoamine transport GO:0015844 9.76 SLC6A4 SLC6A2
5 neurotransmitter catabolic process GO:0042135 9.73 MAOA COMT
6 positive regulation of behavioral fear response GO:2000987 9.67 GRP GRPR
7 positive regulation of respiratory gaseous exchange GO:1903942 9.56 GRPR GRP
8 catecholamine metabolic process GO:0006584 9.51 MAOA COMT
9 psychomotor behavior GO:0036343 9.46 GRPR GRP
10 neurotransmitter reuptake GO:0098810 9.32 SLC6A4 SLC6A2
11 neuropeptide signaling pathway GO:0007218 9.32 NPSR1 HCRTR1 GRPR GRP GLRB
12 response to external biotic stimulus GO:0043207 9.26 GRPR GRP

Molecular functions related to Agoraphobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serotonin binding GO:0051378 9.26 SLC6A4 HTR1A
2 monoamine transmembrane transporter activity GO:0008504 8.92 SLC6A4 SLC6A2

Sources for Agoraphobia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....